Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 4

REGENERON PHARMACEUTICALS INC

Form 4

February 08, 2012

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB Number: 3235-0287

Estimated average

Check this box if no longer subject to Section 16.

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Expires: January 31, 2005

OMB APPROVAL

Form 4 or Form 5 obligations may continue.

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

burden hours per response... 0.5

See Instruction 1(b).

(Print or Type Responses)

| 1. Name and Address of Reporting Person * GOLDBERG MURRAY A | | | 2. Issuer Name and Ticker or Trading Symbol REGENERON PHARMACEUTICALS INC [REGN] | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner |
|---|------------|----------|---|--|
| (Last) | (First) | (Middle) | 3. Date of Earliest Transaction (Month/Day/Year) | X Officer (give title Other (specify below) SVP Finance and Admin CFO Trea |
| 777 OLD SAW MILL RIVER ROAD | | | 02/06/2012 | 5 T Timalee and Tallian GT o Tiea |
| | (Street) | | 4. If Amendment, Date Original | 6. Individual or Joint/Group Filing(Check |
| TARRYTO | WN, NY 103 | 591 | Filed(Month/Day/Year) | Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person |
| (City) | (State) | (Zip) | Table I Non Derivative Securities A | equired Disposed of ar Reposicially Owned |

| (City) | (State) | (Zip) Tab | le I - Non-I | Derivative | Secur | ities Acqui | red, Disposed of, | or Beneficiall | y Owned |
|--------------------------------------|--------------------------------------|---|--|---|---------|-------------|--|--|---|
| 1.Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transactic Code (Instr. 8) | 4. Securit onor Dispos (Instr. 3, 4 | ed of (| ` ′ | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
| Common Stock | 02/06/2012 | | M(1) | 18,750 | A | \$ 16.8 | 105,861 | D | |
| Common Stock | 02/06/2012 | | F(1) | 3,206 | D | \$ 98.23 | 102,655 | D | |
| Common Stock | 02/06/2012 | | F(1) | 7,160 | D | \$ 98.23 | 95,495 | D | |
| Common Stock | 02/06/2012 | | M(1) | 9,375 | A | \$ 21.25 | 104,870 | D | |
| | 02/06/2012 | | F(1) | 2,027 | D | \$ 98.23 | 102,843 | D | |

Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 4

| Common Stock | | | | | | | | |
|-----------------|------------|--------------|--------|---|---------------------|---------|---|-------------------|
| Common Stock | 02/06/2012 | F <u>(1)</u> | 3,384 | D | \$ 98.23 | 99,459 | D | |
| Common Stock | 02/06/2012 | M(1) | 12,788 | A | \$ 24.86 | 112,247 | D | |
| Common Stock | 02/06/2012 | F(1) | 3,236 | D | \$ 98.23 | 109,011 | D | |
| Common Stock | 02/06/2012 | F <u>(1)</u> | 4,400 | D | \$ 98.23 | 104,611 | D | |
| Common Stock | 02/07/2012 | S <u>(1)</u> | 13,265 | D | \$ 99.67 (2) | 91,346 | D | |
| Common Stock | 02/07/2012 | S <u>(1)</u> | 3,735 | D | \$ 100.42 (3) | 87,611 | D | |
| Common Stock | 02/07/2012 | S <u>(1)</u> | 500 | D | \$ 101.35 (4) | 87,111 | D | |
| Common Stock | | | | | | 5,416 | I | By 401(k) Plan |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474

(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transactio Code (Instr. 8) | 5. Number of onDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | | 7. Title and Amo Underlying Secu (Instr. 3 and 4) | |
|---|---|--------------------------------------|---|--|---|--|--------------------|---|------------------------|
| | | | | Code V | (A) (D) | Date Exercisable | Expiration Date | Title | An or Nu of S |
| Non-Qualified Stock Option (right to buy) | \$ 16.8 | 02/06/2012 | | M <u>(1)</u> | 18,750 | <u>(5)</u> | 12/17/2018 | Common Stock | 18 |
| Non-Qualified Stock Option | \$ 21.25 | 02/06/2012 | | M <u>(1)</u> | 9,375 | <u>(5)</u> | 12/18/2019 | Common Stock | 9. |

Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 4

(right to buy)

Non-Qualified

Stock Option (right to buy)

\$ 24.86 02/06/2012

 $M_{-}^{(1)}$

12,788 07/05/2010 12/15/2014

Common Stock

Reporting Owners

Reporting Owner Name / Address Relationships

Director 10% Owner Officer

Other

GOLDBERG MURRAY A 777 OLD SAW MILL RIVER ROAD TARRYTOWN, NY 10591

SVP Finance and Admin CFO Trea

Signatures

By: /s/**Douglas S. McCorkle For: /s/**Murray A. Goldberg

02/08/2012

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
- Represents volume-weighted average price of sales of 13,265 shares of Company stock on February 7, 2012 at prices ranging from (2) \$99.22 to \$99.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 7, 2012 at each separate price.
- Represents volume-weighted average price of sales of 3,735 shares of Company stock on February 7, 2012 at prices ranging from (3) \$100.00 to \$100.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 7, 2012 at each separate price.
- Represents volume-weighted average price of sales of 500 shares of Company stock on February 7, 2012 at prices ranging from \$101.33 (4) to \$101.41. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 7, 2012 at each separate price.
- (5) The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant.
- (6) Exercisable date, exercise date, exercise price, purchase price, sales price, and/or expiration date is/are not applicable in this case.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 3